Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Long-term safety & tolerability of pelacarsen(TQJ230) in participants who completed the parent trial

Cardiology
Ailin Barseghian Elfarra
A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial
Cardiovascular Disease
Heart - Cardiovascular Circulatory

Study Description

This study will allow to evaluate a long-term safety and tolerability of pelacarsen (TQJ230) 80 mg QM in patients. All consenting participants from the parent study who meet the eligibility criteria will be participating in this open label extension study. The maximum duration of this study is approximately 5 years.

Eligibility

  1. Signed informed consent
  2. Participant has successfully completed the parent study and is considered safe to participate by Investigator's clinical judgement.
  1. Any medical condition(s) that may put the participant at risk in the investigator's opinion
  2. Pregnant or nursing (lactating) women
  3. Women of child-bearing potential, unless they are using effective methods of contraception during dosing and for 16 weeks (= 5 times the terminal half-life) after stopping of study medication
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.